NICE backs use of Boehringer’s Ofev in IPF from diagnosis
pharmaphorum
DECEMBER 15, 2022
Ofev (nintedanib) has been recommended since 2015 for NHS use in IPF patients who have a forced vital capacity (FVC) value of 50% to 80% of normal, but will now be an option for people with less severe disease, i.e. an FVC of more than 80%. The post NICE backs use of Boehringer’s Ofev in IPF from diagnosis appeared first on.
101 
Let's personalize your content